EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...

The FDA has developed draft guidance addressing confusion and legal action over the naming and labeling of plant-based alternatives to eggs, seafood, poultry, meat and dairy (excluding plant-based ...

Based on the TRAVERSE trial results, the FDA has recommended that the Boxed Warning related to an increased risk of adverse cardiovascular outcomes be removed from the labels of testosterone products.

A urine drug test can quickly detect both illegal and prescription drugs in a person’s system. Doctors, sports officials, and many employers require these tests. Signs of drug use can remain in ...

Xilio expects to report updated data from the Phase 2 clinical trial in the middle of 2025, including additional response assessments and follow-up. In addition, Xilio continues to enroll patients in ...

In addition, Xilio continues to enroll patients in Phase 1C (combination dose escalation) evaluating vilastobart at the 150 mg Q6W dose level in combination with atezolizumab at 1200 mg Q3W.

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial (NCT06712355 ) evaluating BNT327 plus chemotherapy compared to atezolizumab plus chemotherapy ... a TROP2-targeted ...